BRII-732
HIV (PrEP)
Phase 1Clinical Hold (FDA)
Key Facts
About Brii Biosciences
Founded in 2018, Brii Biosciences is a publicly traded biotech with a mission to address major public health challenges in infectious diseases and CNS disorders. Its core strategy involves in-licensing and co-developing clinical-stage assets, most notably achieving the first NMPA-approved COVID-19 neutralizing antibody combination in China. The company operates with a dual-US/China footprint, aiming to accelerate global innovation for patients in high-need markets.
View full company profile